| Autor: |
Sperger JM; Jamie M. Sperger, PhD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI; Felix Y. Feng, MD, Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, UCSF, Department of Radiation Oncology, Department of Urology, University of California San Francisco, San Francisco, CA; Andrew J. Armstrong, MD, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Shuang G. Zhao, MD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Human Oncology, University of Wisconsin, Madison, WI, William S. Middleton Memorial Veterans Hospital, Madison, WI; and Joshua M. Lang, MD, MS, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Medicine, University of Wisconsin, Madison, WI., Feng FY; Jamie M. Sperger, PhD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI; Felix Y. Feng, MD, Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, UCSF, Department of Radiation Oncology, Department of Urology, University of California San Francisco, San Francisco, CA; Andrew J. Armstrong, MD, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Shuang G. Zhao, MD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Human Oncology, University of Wisconsin, Madison, WI, William S. Middleton Memorial Veterans Hospital, Madison, WI; and Joshua M. Lang, MD, MS, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Medicine, University of Wisconsin, Madison, WI., Armstrong AJ; Jamie M. Sperger, PhD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI; Felix Y. Feng, MD, Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, UCSF, Department of Radiation Oncology, Department of Urology, University of California San Francisco, San Francisco, CA; Andrew J. Armstrong, MD, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Shuang G. Zhao, MD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Human Oncology, University of Wisconsin, Madison, WI, William S. Middleton Memorial Veterans Hospital, Madison, WI; and Joshua M. Lang, MD, MS, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Medicine, University of Wisconsin, Madison, WI., Zhao SG; Jamie M. Sperger, PhD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI; Felix Y. Feng, MD, Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, UCSF, Department of Radiation Oncology, Department of Urology, University of California San Francisco, San Francisco, CA; Andrew J. Armstrong, MD, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Shuang G. Zhao, MD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Human Oncology, University of Wisconsin, Madison, WI, William S. Middleton Memorial Veterans Hospital, Madison, WI; and Joshua M. Lang, MD, MS, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Medicine, University of Wisconsin, Madison, WI., Lang JM; Jamie M. Sperger, PhD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI; Felix Y. Feng, MD, Helen Diller Family Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Medicine, UCSF, Department of Radiation Oncology, Department of Urology, University of California San Francisco, San Francisco, CA; Andrew J. Armstrong, MD, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; Shuang G. Zhao, MD, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Human Oncology, University of Wisconsin, Madison, WI, William S. Middleton Memorial Veterans Hospital, Madison, WI; and Joshua M. Lang, MD, MS, Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI, Department of Medicine, University of Wisconsin, Madison, WI. |
| Abstrakt: |
Competing Interests: Felix Y. FengStock and Other Ownership Interests: ArteraConsulting or Advisory Role: Janssen Biotech, Myovant Sciences, Astellas Pharma, SerImmune, Foundation Medicine, Exact Sciences, Bristol Myers Squibb, Varian Medical Systems, Novartis, Roivant, BayerResearch Funding: Zenith Epigenetics Andrew J. ArmstrongConsulting or Advisory Role: Bayer, Dendreon, Pfizer, Astellas Scientific and Medical Affairs Inc, Clovis Oncology, AstraZeneca, Merck, Bristol Myers Squibb, Janssen, FORMA TherapeuticsResearch Funding: Dendreon (Inst), Bayer (Inst), Pfizer (Inst), Novartis (Inst), Janssen Oncology (Inst), Astellas Pharma (Inst), Gilead Sciences (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Constellation Pharmaceuticals (Inst), Merck (Inst), AstraZeneca (Inst), BeiGene (Inst), Amgen (Inst), FORMA Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: Circulating tumor cell novel capture technologyTravel, Accommodations, Expenses: Astellas Scientific and Medical Affairs Inc Shuang G. ZhaoEmployment: Exact Sciences (I)Stock and Other Ownership Interests: Exact Sciences (I) Joshua M. LangStock and Other Ownership Interests: Salus DiscoveryConsulting or Advisory Role: Sanofi, Immunomedics¸ Janssen, Pfizer/Astellas, 4D PharmaResearch Funding: Medivation, Agensys, GlaxoSmithKline, Immunomedics, Bristol Myers Squibb, JanssenPatents, Royalties, Other Intellectual Property: I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.No other potential conflicts of interest were reported. |
